ADHD in Adults and Special Populations

Why Adults Are Diagnosed Differently

• Kaplan & Sadock's Comprehensive Textbook of Psychiatry, p. 11327
• The Maudsley Prescribing Guidelines in Psychiatry, 15th ed., p. 823

Clinical Features in Adults

• Core symptoms persist but shift in expression: overt hyperactivity becomes inner restlessness; impulsivity manifests as sudden decision-making, emotional dysregulation, and interpersonal conflicts
• Inattention dominates: difficulty organising and completing work, inability to concentrate, increased distractibility, missing deadlines
• Impulsivity: acting without considering consequences, difficulty waiting, interrupting others
• Many adults develop secondary depression related to chronic underperformance, low self-esteem, and occupational/social failures
• The combined presentation (inattentive + hyperactive-impulsive) is most common in clinical referrals; purely inattentive adults are often undiagnosed longest

• Kaplan and Sadock's Synopsis of Psychiatry, p. 448-449

Diagnosis

1. Comprehensive specialist assessment - conducted by someone trained in adult ADHD
2. Retrospective confirmation of childhood onset - symptoms must have been present before age 12 (DSM-5); collateral history from parents or teachers is helpful
3. Current impairment in at least one domain (work, relationships, daily life)
4. Validated diagnostic interview - the DIVA-5 (Diagnostic Interview for ADHD in Adults, DSM-5 based) is recommended
5. Rule out alternative causes: anxiety, mood disorders, sleep disorders, substance use, thyroid disease - all can mimic ADHD

Paul Wender (University of Utah) was a pioneering figure who developed criteria for adult ADHD as early as the 1970s, requiring retrospective childhood diagnosis + current adult impairment.

• Maudsley Prescribing Guidelines, p. 823
• Kaplan and Sadock's Synopsis of Psychiatry, p. 449

Pharmacological Treatment

First-Line: Stimulants

Evidence from network meta-analyses supports amphetamines as having a higher effect size than methylphenidate in adults, though individual response varies.

Second-Line / Alternatives: Non-Stimulants

• Medication only after environmental modifications have been tried and reviewed
• Specialist-initiated only, after comprehensive mental/physical/social assessment
• Try methylphenidate or lisdexamfetamine first; if one fails after a 6-week adequate-dose trial, switch to the other before considering atomoxetine
• Review medication at least annually; consider "off-days" or dose reduction to minimise long-term risk
• ECG is not required before starting if cardiovascular history and exam are normal
• Maudsley Prescribing Guidelines, p. 823-825

Non-Pharmacological Treatments

• Omega-3 fatty acid supplementation - small but significant positive effects in well-controlled trials
• ADHD coaching, mindfulness, meditation, yoga - popular but insufficient scientific data for general recommendation
• EEG neurofeedback - a 2025 JAMA Psychiatry meta-analysis (PMID 39661381) provides updated systematic evidence
• Digital tools (electronic reminders, scheduling apps) - widely used
• Occupational counselling and academic accommodations - under the Americans with Disabilities Act (ADA), adults with ADHD are entitled to reasonable workplace and educational accommodations

• Kaplan & Sadock's Comprehensive Textbook of Psychiatry, p. 11329

Special Populations

Transitional-Age Youth (Ages 16-26)

• Increased risk: substance use, academic underperformance, occupational failure, relationship difficulties
• Irregular schedules (e.g., college) may make extended-release morning doses insufficient - judicious use of IR boosters may be needed
• Clinicians should counsel on responsible sexual activity, alcohol/drug use, and medication management
• Stimulant misuse among college students is well-documented; IR formulations are the most diverted; white male students at competitive universities with fraternity affiliation and prior conduct problems are highest risk

ADHD + Substance Use Disorders

• Prefer non-stimulants (atomoxetine) as first choice
• Close liaison with addiction specialist is required before prescribing controlled stimulants
• Lisdexamfetamine (as a prodrug) has lower misuse liability than IR amphetamines
• Use extended-release preparations if stimulants are prescribed
• A clinical case example: a woman with childhood ADHD and methamphetamine dependence - after residential detox, nonstimulant treatment produced a good response
• Maudsley: lisdexamfetamine is specifically associated with improved outcomes in those with co-occurring amphetamine/methamphetamine use disorders

ADHD + Comorbid Psychiatric Disorders

• Bipolar disorder or psychosis: ADHD stimulants may worsen these conditions - use with great caution
• Anxiety + ADHD: sequential pharmacotherapy (stimulant OR SSRI) treating the most distressing condition first; combination can be considered
• Depression: secondary depression is common in ADHD adults; address both - bupropion has dual utility
• Comorbid ADHD + AUD/drug dependence: scant RCT evidence; individualise treatment

ADHD in Women

ADHD in Older Adults

Prognosis and Long-Term Outcomes

• Adults with untreated ADHD have poorer outcomes across employment, relationships, physical health, and mental health compared to both non-ADHD individuals and those receiving treatment
• However, assumptions about long-term medication benefit are currently unsubstantiated - RCT data beyond 52 weeks is scarce; short-term trials show improvement in inattentiveness and restlessness more consistently than quality-of-life measures
• National organisations such as CHADD and APSARD provide reliable patient resources and are actively developing the first US clinical guidelines for adult ADHD (in final review stages as of 2026)

• Kaplan & Sadock's Comprehensive Textbook of Psychiatry, pp. 11327-11330
• Kaplan and Sadock's Synopsis of Psychiatry, pp. 448-449
• The Maudsley Prescribing Guidelines in Psychiatry, 15th ed., pp. 822-825
• Recent evidence: Popit et al., 2024 - ADHD prevalence meta-analysis (PMID 39381949) | Westwood et al., 2025 - Neurofeedback meta-analysis in JAMA Psychiatry (PMID 39661381) | Bellato et al., 2025 - Pharmacotherapy and QoL network meta-analysis (PMID 38823477)